Atossa Therapeutics Raises $4.5 Million to Support Oncology Clinical Development Efforts

Atossa Therapeutics (ATOS) successfully finalizes a registered direct offering, generating approximately $4.5 million. This funding is crucial as the company progresses its clinical efforts aimed at addressing significant unmet medical needs in oncology.

New Funding Aims for Clinical Development

The offering involves 1,363,637 shares along with Series A and Series B warrants. If all warrants are exercised, Atossa could potentially receive an additional $12 million, enhancing its financial position. The Series A warrants have a lifespan of 5.5 years, while the Series B warrants are valid for 2 years. Rodman & Renshaw LLC serves as the exclusive placement agent for this transaction.

Commitment to Innovative Oncology Therapies

Atossa intends to utilize the net proceeds primarily for clinical development and working capital. This focus aligns with its ongoing commitment to providing innovative therapies in oncology. The company’s lead product candidate, (Z)-endoxifen, is currently undergoing various stages of clinical development, exemplifying Atossa’s drive to meet critical health needs.

Forward-Looking Statements Provided

Atossa emphasizes the variability in potential proceeds from the offering based on the exercise of the warrants. Recent updates about these developments are available on the SEC website and Atossa’s corporate site, keeping stakeholders informed and engaged.